BBLG
Income statement / Annual
Last year (2024), Bone Biologics Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Bone Biologics Corporation's net income was -$7.32 M.
See Bone Biologics Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$50.00
|
$96.00
|
$96.00
|
$700.00
|
$4,451.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$50.00
|
-$96.00
|
-$96.00
|
-$700.00
|
-$4,451.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.13 M
|
$6.91 M
|
$1.58 M
|
$82,044.00
|
$340,672.00
|
$1.10 M
|
$104,490.00
|
-$1.19 M
|
$11.60 M
|
$3.67 M
|
| General & Administrative Expenses |
$2.09 M
|
$2.52 M
|
$2.09 M
|
$1.02 M
|
$484,342.00
|
$1.35 M
|
$2.69 M
|
$3.82 M
|
$6.25 M
|
$8.33 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.09 M
|
$2.52 M
|
$2.09 M
|
$1.02 M
|
$484,342.00
|
$1.35 M
|
$2.69 M
|
$3.82 M
|
$6.25 M
|
$8.33 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$104,490.00
|
$2.63 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$4.22 M
|
$9.43 M
|
$3.67 M
|
$1.10 M
|
$825,014.00
|
$2.45 M
|
$2.79 M
|
$2.63 M
|
$17.85 M
|
$12.00 M
|
| Cost And Expenses |
$0.00
|
$9.43 M
|
$3.67 M
|
$1.10 M
|
$825,014.00
|
$2.45 M
|
$2.79 M
|
$2.63 M
|
$17.85 M
|
$12.00 M
|
| Interest Income |
$55,660.00
|
$1,868.00
|
$731.71
|
$805.11
|
$998.08
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$805,109.00
|
$998,076.00
|
$975,774.00
|
$1.23 M
|
$4.42 M
|
$3.17 M
|
$1.87 M
|
| Depreciation & Amortization |
$0.00
|
$9.43 M
|
$3.67 M
|
$1.10 M
|
$50.00
|
$50.00
|
$96.00
|
$96.00
|
$700.00
|
$4,451.00
|
| EBITDA |
-$4.22 M |
$479,572.00 |
$0.00 |
$0.00 |
-$825,014.00 |
-$2.45 M |
-$2.79 M |
-$2.63 M |
-$20.41 M |
-$11.99 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$3.11 M
|
$479,572.00
|
$2.18 M
|
-$507,609.00
|
-$998,076.00
|
-$975,774.00
|
-$1.64 M
|
-$4.42 M
|
-$614,693.00
|
-$1.87 M
|
| Income Before Tax |
-$7.32 M
|
-$8.95 M
|
-$1.48 M
|
-$1.61 M
|
-$1.82 M
|
-$3.42 M
|
-$4.43 M
|
-$7.05 M
|
-$21.03 M
|
-$13.87 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$2.18 M
|
$1,600.00
|
$1,600.00
|
$1,603.00
|
$1,729.00
|
$1,600.00
|
$2,243.00
|
$8,840.00
|
| Net Income |
-$7.32 M
|
-$8.95 M
|
$695,933.00
|
-$1.61 M
|
-$1.82 M
|
-$3.42 M
|
-$4.43 M
|
-$7.05 M
|
-$21.03 M
|
-$13.88 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-4.83 |
-34.01 |
-31.15 |
-37.35 |
-35.68 |
-66.97 |
0 |
0 |
0 |
0 |
| EPS Diluted |
-4.83 |
-34.01 |
-31.15 |
-37.35 |
-35.68 |
-66.97 |
0 |
0 |
0 |
0 |
| Weighted Average Shares Out |
$1.52 M
|
$263,137.00
|
$47,000.00
|
$43,000.00
|
$51,000.00
|
$51,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$1.52 M
|
$263,137.00
|
$47,658.00
|
$43,127.00
|
$51,138.00
|
$51,138.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
